Intelligence Feed event · Policy · 2026-09-03

    NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival

    Question

    NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival

    Direct answer

    The New England Journal of Medicine published Phase 1/2 trial findings evaluating Revolution Medicines' daraxonrasib (RASONQUE) in metastatic non-small cell lung cancer harboring RAS mutations. The study recorded a 42% objective response rate and 16.0 months median overall survival in patients previously treated with docetaxel, establishing clinical benchmark data for the compound.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/nejm-publishes-revolution-medicines-daraxonrasib-nsclc-data-42-orr-16-0-mo-survi-5229d5

    POLICY
    NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival
    The New England Journal of Medicine published Phase 1/2 trial findings evaluating Revolution Medicines' daraxonrasib (RASONQUE) in metastatic non-small cell lung cancer harboring RAS mutations. The study recorded a 42% objective response rate and 16.0 months median overall survival in patients previously treated with docetaxel, establishing clinical benchmark data for the compound.
    RVMD
    Impact
    68
    SEP 3
    SIG
    90%
    RVMD
    NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival
    The New England Journal of Medicine published Phase 1/2 trial findings evaluating Revolution Medicines' daraxonrasib (RASONQUE) in metastatic non-small cell lung cancer harboring RAS mutations. The study recorded a 42% objective response rate and 16.0 months median overall survival in patients previously treated with docetaxel, establishing clinical benchmark data for the compound.
    → Positive Phase 1/2 peer-reviewed clinical data lowers regulatory approval risk for RVMD oncology pipeline.
    Impact
    The New England Journal of Medicine published Phase 1/2 trial findings evaluating Revolution Medicines' daraxonrasib (RASONQUE) in metastatic non-small cell lung cancer harboring RAS mutations. The study recorded a 42% objective response rate and 16.0 months median overall survival in patients previously treated with docetaxel, establishing clinical benchmark data for the compound.
    Affected
    RVMD
    Transmission
    Positive Phase 1/2 peer-reviewed clinical data lowers regulatory approval risk for RVMD oncology pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDclinical pipeline de-risking boosting biotechnology valuationUp1-5dNEJM publication of Phase 1/2 daraxonrasib trial showing 42% ORR and 16.0 months median OS.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month